AVDL

Avadel Pharmaceuticals

8.31 USD
+0.04
0.48%
At close Apr 23, 4:00 PM EDT
After hours
8.31
+0.00
0.00%
1 day
0.48%
5 days
5.46%
1 month
-2.58%
3 months
4.66%
6 months
-37.14%
Year to date
-24.45%
1 year
-54.06%
5 years
-15.81%
10 years
-47.60%
 

About: Avadel Pharmaceuticals PLC is a specialty pharmaceutical company. The group focused on transforming medicines to transform lives. It provides solutions to the development of medications that address the challenges patients face with current treatment options. The company is engaged in the development of differentiated drug products for administration in various forms such as capsules, tablets, injectables etc. Its commercialized product LUMRYZ is an extended-release formulation of sodium oxybate indicated to be taken once at bedtime for the treatment of cataplexy or EDS in adults with narcolepsy. It operates in one segment, the development and commercialization of pharmaceutical products, including controlled-release therapeutic products based on its proprietary polymer-based technology.

Employees: 188

0
Funds holding %
of 7,419 funds
0
Analysts bullish %
of 3 analysts

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

104% more call options, than puts

Call options by funds: $26.4M | Put options by funds: $12.9M

70% more repeat investments, than reductions

Existing positions increased: 68 | Existing positions reduced: 40

4.92% more ownership

Funds ownership: 77.33% [Q3] → 82.24% (+4.92%) [Q4]

10% less funds holding

Funds holding: 175 [Q3] → 157 (-18) [Q4]

13% less funds holding in top 10

Funds holding in top 10: 8 [Q3] → 7 (-1) [Q4]

15% less capital invested

Capital invested by funds: $976M [Q3] → $833M (-$143M) [Q4]

43% less first-time investments, than exits

New positions opened: 23 | Existing positions closed: 40

Research analyst outlook

3 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$12
44%
upside
Avg. target
$17.33
109%
upside
High target
$21
153%
upside

3 analyst ratings

positive
100%
neutral
0%
negative
0%
Needham
Ami Fadia
14% 1-year accuracy
23 / 164 met price target
129%upside
$19
Buy
Reiterated
9 Apr 2025
HC Wainwright & Co.
Oren Livnat
50% 1-year accuracy
25 / 50 met price target
153%upside
$21
Buy
Reiterated
4 Mar 2025
Deutsche Bank
David Hoang
12% 1-year accuracy
2 / 17 met price target
44%upside
$12
Buy
Initiated
11 Feb 2025

Financial journalist opinion

Based on 5 articles about AVDL published over the past 30 days

Neutral
GlobeNewsWire
6 days ago
Avadel and nference Announce Publication of Real-World Data on Sodium Oxybate Treatment Patterns in the Journal of Clinical Neuroscience
-- Retrospective analysis reveals no significant differences in comorbidities in narcolepsy patients treated vs. not treated with sodium oxybate -- -- One third of patients taking immediate-release, twice-nightly sodium oxybate discontinued treatment, most often due to lack of efficacy; inability to wake up was most common reason for missing second nightly dose -- DUBLIN, April 17, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, and  nference , a health tech company dedicated to making biomedical data computable, today announced the publication of real-world data on comorbidities and treatment patterns of people with narcolepsy treated versus not treated with immediate-release sodium oxybate.
Avadel and nference Announce Publication of Real-World Data on Sodium Oxybate Treatment Patterns in the Journal of Clinical Neuroscience
Neutral
GlobeNewsWire
1 week ago
Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
DUBLIN, April 10, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, today announced that the Compensation Committee of Avadel's Board of Directors approved the grant of non-statutory options to nine (9) new employees to purchase 48,400 ordinary shares under Avadel's 2021 Inducement Plan. The awards were granted as an inducement material to the employee's acceptance of employment with Avadel in accordance with Nasdaq Listing Rule 5635(c)(4). The options have a ten-year term and vest over four years, with 25% vesting on the one-year anniversary of each new employee's respective start date and 25% vesting on the second, third, and fourth anniversary thereafter. The options are subject to the terms and conditions of Avadel's 2021 Inducement Plan approved by the Board of Directors in November 2021 and the terms and conditions of award agreements covering the grants.
Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Neutral
GlobeNewsWire
2 weeks ago
Avadel Pharmaceuticals Provides Update at Needham Virtual Healthcare Conference
DUBLIN, April 08, 2025 (GLOBE NEWSWIRE) --  Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, today presented at the 24th Annual Needham Virtual Healthcare Conference.
Avadel Pharmaceuticals Provides Update at Needham Virtual Healthcare Conference
Neutral
GlobeNewsWire
3 weeks ago
Avadel Pharmaceuticals to Present at the 24th Annual Needham Healthcare Conference
DUBLIN, April 01, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that members of management will participate in a fireside chat at the 24th Annual Needham Healthcare Conference on Tuesday, April 8 at 1:30 p.m. ET.
Avadel Pharmaceuticals to Present at the 24th Annual Needham Healthcare Conference
Neutral
GlobeNewsWire
4 weeks ago
Avadel Announces Publications in CNS Drugs Supplement Highlighting Key Clinical Issues for People with Narcolepsy and Their Clinicians
DUBLIN, March 25, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, today announced the publication of six manuscripts covering clinical management, shared decision-making and goal setting for people with narcolepsy and their clinicians in a CNS Drugs supplement titled “A New Dawn in the Management of Narcolepsy”.
Avadel Announces Publications in CNS Drugs Supplement Highlighting Key Clinical Issues for People with Narcolepsy and Their Clinicians
Neutral
GlobeNewsWire
1 month ago
Avadel Pharmaceuticals to Present at Upcoming Investor Conferences
DUBLIN, Ireland, March 05, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that members of management will participate in the following upcoming investor conferences: Leerink Global Biopharma Conference: Fireside chat on Wednesday, March 12 at 9:20 a.m. ET. UBS Virtual CNS Day: Fireside chat on Monday, March 17 at 8:30 a.m.
Avadel Pharmaceuticals to Present at Upcoming Investor Conferences
Neutral
Seeking Alpha
1 month ago
Avadel Pharmaceuticals plc (AVDL) Q4 2024 Earnings Call Transcript
Avadel Pharmaceuticals plc (NASDAQ:AVDL ) Q4 2024 Earnings Conference Call March 3, 2025 8:30 AM ET Company Participants Austin Murtagh - Precision AQ Gregory Divis - Chief Executive Officer Thomas McHugh - Chief Financial Officer Conference Call Participants François Brisebois - Oppenheimer Poorna Kannan - Needham & Company Oren Livnat - H.C. Wainwright & Co. David Amsellem - Piper Sandler & Co. Madhumita Yennawar - Leerink Partners Myriam Belghiti - LifeSci Capital David Hoang - Deutsche Bank AG Brandon Folkes - Rodman & Renshaw Research Operator Greetings, and welcome to Avadel Pharmaceuticals' Fourth Quarter and Business Update Conference Call.
Avadel Pharmaceuticals plc (AVDL) Q4 2024 Earnings Call Transcript
Neutral
GlobeNewsWire
1 month ago
Avadel Pharmaceuticals Reiterates 2025 Guidance as it Reports Fourth Quarter and Full Year 2024 Financial Results
-- LUMRYZ™ generated $50.4 million in sales in the fourth quarter, up 158% year-over-year, taking the full-year total to $169.1 million, in line with preliminary results published January 8 -- Reiterates 2025 guidance, with the number of patients on LUMRYZ expected to increase to 3,300-3,500 by year-end, generating $240-$260 million in net product revenue and cash flow of $20-40 million -- Executing multiple initiatives to accelerate patient demand for LUMRYZ -- Patient enrollment is on track in the Phase 3 REVITALYZ™ study to evaluate efficacy and safety of LUMRYZ in Idiopathic Hypersomnia (IH) -- Avadel management to host a conference call today at 8:30 a.m. ET DUBLIN, March 03, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, today announced its financial results for the fourth quarter and full year ended December 31, 2024.
Avadel Pharmaceuticals Reiterates 2025 Guidance as it Reports Fourth Quarter and Full Year 2024 Financial Results
Neutral
GlobeNewsWire
1 month ago
Avadel Pharmaceuticals to Provide a Corporate Update and Report Fourth Quarter and Full Year 2024 Financial Results on March 3
DUBLIN, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that it will host a conference call and live webcast at 8:30 a.m. ET on Monday, March 3, 2025, to provide a corporate update and discuss the Company's financial results for the fourth quarter and full year ended December 31, 2024.
Avadel Pharmaceuticals to Provide a Corporate Update and Report Fourth Quarter and Full Year 2024 Financial Results on March 3
Neutral
GlobeNewsWire
1 month ago
Avadel Pharmaceuticals Appoints Kevin Springman as Vice President of Sales
DUBLIN, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced that Kevin Springman has joined the company as Vice President of Sales. Mr. Springman is an accomplished executive with experience leading sales, market access and commercial teams, and executing rare disease drug launches in competitive markets.
Avadel Pharmaceuticals Appoints Kevin Springman as Vice President of Sales
Charts implemented using Lightweight Charts™